{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:26:45Z","timestamp":1793413605850,"version":"4.5.0"},"reference-count":208,"publisher":"American Chemical Society (ACS)","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Chem."],"published-print":{"date-parts":[[2025,2,13]]},"DOI":"10.1021\/acs.jmedchem.4c02547","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:22:21Z","timestamp":1738225341000},"page":"2255-2300","source":"Crossref","is-referenced-by-count":17,"title":["Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-2513","authenticated-orcid":true,"given":"Xueqing","family":"Wang","sequence":"first","affiliation":[{"name":"AbbVie Inc., 1000 Gateway Blvd, South San Francisco, California 94080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Tse","sequence":"additional","affiliation":[{"name":"AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvani","family":"Singh","sequence":"additional","affiliation":[{"name":"AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"ref1\/cit1","unstructured":"About Cystic Fibrosis. Cystic Fibrosis Foundation, https:\/\/www.cff.org\/intro-cf\/about-cystic-fibrosis (accessed Dec 8, 2024)."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2475911"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1126\/science.2570460"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1126\/science.2772657"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.024"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815287115"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1712984"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2391-y"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1501361"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-018-0234-z"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e14-04-0935"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90398-X"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1038\/347358a0"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-117-8_4"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-861-7:183"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010023"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.08.013"},{"key":"ref18\/cit18","unstructured":"AbbVie to Host First Quarter 2023 Earnings\nConference Call, 2023. https:\/\/investors.abbvie.com\/events\/event-details\/abbvie-host-first-quarter-2023-earnings-conference-call."},{"key":"ref19\/cit19","unstructured":"Sionna Therapeutics Announces Phase 1 Initiation\nFor Sion-109 In\nCystic Fibrosis, 2023. https:\/\/www.sionnatx.com\/press-releases\/sionna-therapeutics-announces-phase-1-initiation-for-sion-109-in-cystic-fibrosis\/."},{"key":"ref20\/cit20","unstructured":"Sionna Therapeutics Expands Pipeline With\nMultiple Clinical Stage\nCystic Fibrosis Compounds Through A License Agreement With Abbvie, 2024.https:\/\/www.sionnatx.com\/press-releases\/sionna-therapeutics-expands-pipeline-with-multiple-clinical-stage-cystic-fibrosis-compounds-through-a-license-agreement-with-abbvie\/."},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.3c00310"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01316-5"},{"key":"ref23\/cit23","unstructured":"CFTR2\nwebsite, https:\/\/cftr2.org\/mutations_history\/ (accessed Dec 8, 2024)."},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)00023-0"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90353-R"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ge.29.120195.004021"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.31.21873"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990318"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1002\/1099-0496(200012)30:6<476::AID-PPUL7>3.0.CO;2-O"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.45.28463"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1038\/362160a0"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.02.006"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3849"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.004"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.11.007"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-840OE"},{"key":"ref37\/cit37","unstructured":"Davis, B.\n                      Northern American Cystic Fibrosis Conference, Plenary Session 1\n                      , 2020. https:\/\/www.youtube.com\/watch?v=XWPa1UWJHCs&list=PLhoQ6vyZhgqqFW-h_VcTBb1WMuFs3UIWW&index=1."},{"key":"ref38\/cit38","unstructured":"HIT CF and CHOICES; a study investigating\na new triple combination\nCFTR modulator therapy based on organoid responsiveness in people\nwith CF who have rare CFTR mutations. https:\/\/www.cysticfibrosis.org.uk\/get-involved\/clinical-trials\/trialstracker\/119685 (accessed Mar 20, 2023)."},{"key":"ref39\/cit39","unstructured":"https:\/\/www.biospace.com\/eloxx-pharmaceuticals-announces-final-data-assessment-from-phase-2-combination-clinical-trial-of-elx-02-in-class-1-cystic-fibrosis-cf-patients (accessed Jan 29, 2024)."},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36244-2"},{"key":"ref41\/cit41","unstructured":"Cystic Fibrosis Foundantion 2021 Patient\nRegistry Annual Data Report, https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.014"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.009"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201711946"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05854-7"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7611"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02774-2020"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.011"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99184-1"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.092478"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00169.2005"},{"key":"ref53\/cit53","unstructured":"Abela, A. R.; Anderson, C. D.; Bookser, B. C.; Busch, B. B.; Clemens, J. J.; Cleveland, T.; Coon, T. R.; Frieman, B.; Ghirmai, S. G.; Gulevich, A. V.; Hadida Ruah, S. S.; Ishihara, Y.; Khatuya, H.; McCartney, J.; Miller, M. T.; Paraselli, P.; Pierre, F.; Termin, A.; Swift, S. E.; Uy, J.; Vogel, C. V.; Zhou, J.; Grootenhuis, P.\n                      Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator and preparation\n                      . WO2021030556, 2021."},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24898"},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1943SO"},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.01.007"},{"key":"ref57\/cit57","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0276MA"},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105787108"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100665"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00454-9"},{"key":"ref62\/cit62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807119"},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807120"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261800"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.05.046"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-117-8_27"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.028951"},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3201"},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8278"},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050421"},{"key":"ref71\/cit71","unstructured":"HIT-CF Europe, https:\/\/www.hitcf.org\/ (accessed\nMar 20, 2023)."},{"key":"ref72\/cit72","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00465.2017"},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215982110"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.393637"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201711886"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.12.005"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.06.008"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.09.005"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00201-5"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.1021\/jm5012808"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2672"},{"key":"ref83\/cit83","unstructured":"Center for Drug Evaluation and Research, Ivacaftor, Application Number: 203188Orig1s000, Clinical Pharmacology\nand Biopharmaceutics Review(s), 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf."},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241497"},{"key":"ref85\/cit85","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(16)30138-2"},{"key":"ref86\/cit86","unstructured":"Vertex and Concert Pharmaceuticals Complete\nAsset Purchase Agreement\nfor CTP-656, Jul 25, 2017. http:\/\/investors.vrtx.com\/releasedetail.cfm?releaseid=1034371."},{"key":"ref87\/cit87","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00504-5"},{"key":"ref88\/cit88","unstructured":"Vertex to Initiate Phase 3 Development Program\nfor New Once-Daily\nTriple Combination Regimen in People With Cystic Fibrosis, Jul 28, 2021. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-initiate-phase-3-development-program-new-once-daily."},{"key":"ref89\/cit89","unstructured":"Vertex Announces US FDA Approval of ALYFTREK,\na Once-Daily Next-in-Class\nCFTR Modulator for the Treatment of Cystic Fibrosis, Dec 20, 2024. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-alyftrektm-once-daily-next."},{"key":"ref90\/cit90","unstructured":"AbbVie to Assume Full Development and Commercial\nControl of Cystic\nFibrosis Research Program, Oct 24, 2018.https:\/\/news.abbvie.com\/2018-10-24-AbbVie-to-Assume-Full-Development-and-Commercial-Control-of-Cystic-Fibrosis-Research-Program."},{"key":"ref91\/cit91","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01288"},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.281.5.C1734"},{"key":"ref93\/cit93","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303098200"},{"key":"ref94\/cit94","unstructured":"Vanhoutte, F.; Gouy, M.; Haazen, W.; Kanters, D.; De Beckker, G.; Geller, D.; Van de Wal, K. A. Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers, Poster 258; Presented at the 29 Annual North American Cystic Fibrosis Conference, Phoenix, AZ, Oct 8\u201310, 2015."},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.006"},{"key":"ref96\/cit96","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.200609667"},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201912360"},{"key":"ref98\/cit98","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01796"},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01221"},{"key":"ref100\/cit100","unstructured":"PubChem, Navocaftor\n(ABBV-3067), National Library of Medicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/132189640 (accessed\nSept 30, 2024)."},{"key":"ref101\/cit101","unstructured":"Altenbach, R. J.; Bogdan, A.; Coti, G. P. D.; Cowart, M. D.; Greszler, S. N.; Kelgtermans, H.; Kym, P. R.; Van Der Plas, S. E.\n                      Preparation of heteroaryl substituted pyridines for the treatment of cystic fibrosis\n                      . WO2017208115, 2017."},{"key":"ref102\/cit102","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00343"},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.010959"},{"key":"ref104\/cit104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.11.002"},{"key":"ref105\/cit105","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S257474"},{"key":"ref106\/cit106","unstructured":"PubChem, Dirocaftor\n(PTI-808), National Library of Medicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dirocaftor (accessed\nSept 30, 2024)."},{"key":"ref107\/cit107","unstructured":"Munoz, B.; Parks, D.; Bastos, C. M.\n                      Preparation of ivacaftor analogues containing silicon atoms as CFTR modulators\n                      . WO2017177124A1, 2017."},{"key":"ref108\/cit108","unstructured":"Proteostasis Therapeutics\nAnnounces Positive Clinical Results from\nStudies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and\nPatients with Cystic Fibrosis. GlobeNewswire, Dec 11, 2017. https:\/\/www.globenewswire.com\/en\/news-release\/2017\/12\/11\/1251080\/0\/en\/Proteostasis-Therapeutics-Announces-Positive-Clinical-Results-from-Studies-of-PTI-428-PTI-801-and-PTI-808-in-Healthy-Volunteers-and-Patients-with-Cystic-Fibrosis.html."},{"key":"ref109\/cit109","first-page":"246","volume":"53","author":"Ordonez C.","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref110\/cit110","unstructured":"AbbVie R&D\nDeep Dive, Mar 10, 2020https:\/\/investors.abbvie.com\/static-files\/b898880e-7369-40c4-9f5b-e4b999461414."},{"key":"ref111\/cit111","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009761"},{"key":"ref112\/cit112","unstructured":"FDA Approves\nORKAMBI (lumacaftor\/ivacaftor) - the First Medicine\nto Treat the Underlying Cause of Cystic Fibrosis for People Ages 12\nand Older with Two Copies of the F508del Mutation. Vertex, Jul 2, 2015. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-orkambitm-lumacaftorivacaftor-first-medicine-treat."},{"key":"ref113\/cit113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"ref114\/cit114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.02.009"},{"key":"ref115\/cit115","unstructured":"Vertex\nPharmaceuticals, Orkambi (lumacaftor\/ivacaftor, package insert), 2016http:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf."},{"key":"ref116\/cit116","doi-asserted-by":"publisher","DOI":"10.2174\/1872312812666180328105259"},{"key":"ref117\/cit117","first-page":"274","volume":"51","author":"Van Goor F.","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref118\/cit118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"ref119\/cit119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"ref120\/cit120","unstructured":"FDA Approves SYMDEKOTM (tezacaftor\/ivacaftor and ivacaftor) to Treat\nthe Underlying Cause of Cystic Fibrosis in People Ages 12 and Older\nwith Certain Mutations in the CFTR Gene. Vertex, Feb 12, 2018. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-symdekotm-tezacaftorivacaftor-and-ivacaftor-treat."},{"key":"ref121\/cit121","unstructured":"Center for Drug Evaluation and Research, Symdeko (tezacaftor\/ivacaftor) Tablets, Application\nNumber: 210491Orig1s000,\nNon-Clinical Review(s), 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000PharmR.pdf."},{"key":"ref122\/cit122","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01339"},{"key":"ref123\/cit123","first-page":"287","volume":"51","author":"Van de Steen O.","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref124\/cit124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.04.014"},{"key":"ref125\/cit125","unstructured":"Update\non progress in cystic fibrosis programs. Gal\u00e1pagos, Jan 2, 2018. https:\/\/www.glpg.com\/press-releases\/update-on-progress-in-cystic-fibrosis-programs\/."},{"key":"ref126\/cit126","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139983"},{"key":"ref127\/cit127","unstructured":"PubChem, Fdl169, 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide, National Library of Medicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/86298861 (accessed Aug 15, 2024)."},{"key":"ref128\/cit128","unstructured":"Cole, B. M.\n                      Preparation of phthalazinone compounds and methods for the treatment of cystic fibrosis\n                      . US20140274933A1, 2014."},{"key":"ref129\/cit129","first-page":"216","volume":"50","author":"Ferkany J. W.","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref130\/cit130","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(18)30319-9"},{"key":"ref131\/cit131","first-page":"252","volume":"53","author":"Horsley A. R.","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref132\/cit132","unstructured":"Liao, J.; Munson, M.; Gao, Z.; Hurlbut, G.; Macor, J. E.\n                      Preparation of tetrahydroindazole compounds, compositions, and methods of using thereof\n                      . WO2023240267, 2023."},{"key":"ref133\/cit133","unstructured":"Vertex Announces\nPositive Phase 1 & Phase 2 Data from Three Different\nTriple Combination Regimens in People with Cystic Fibrosis Who Have\nOne F508del Mutation and One Minimal Function Mutation (F508del\/Min). Vertex, Jul 18, 2017. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-phase-1-phase-2-data-three-different."},{"key":"ref134\/cit134","unstructured":"PubChem, Olacaftor\n(VX-440), National Library of Medicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/121250885 (accessed\nSep 30, 2024)."},{"key":"ref135\/cit135","unstructured":"Miller, M. T.; Anderson, C.; Arumugam, V.; Bear, B. R.; Binch, H. M.; Clemens, J. J.; Cleveland, T.; Conroy, E.; Coon, T. R.; Frieman, B. A.; Grootenhuis, P. D. J.; Gross, R. S.; Hadida-Ruah, S. S.; Haripada, K.; Joshi, P. V.; Krenitsky, P. J.; Lin, C.C.; Marelius, G. E.; Melillo, V.; McCartney, J.; Nicholls, G. M.; Pierre, F. J. D.; Silina, A.; Termin, A. P.; Uy, J.; Zhou, J.\n                      Preparation of N-aroylsulfonamide derivatives as cystic fibrosis transmembrane conductance regulator modulators\n                      . US20160095858, 2016."},{"key":"ref136\/cit136","unstructured":"Lee, E. C.; Navamal, M.; Nti-Addae, K. W.; Shi, Y.; Shrestha, M.; Zhang, B.; Zwicker, C.\n                      Preparation of pyridinecarboxamides and their crystalline forms as modulators of CFTR\n                      . WO2019191620, 2019."},{"key":"ref137\/cit137","unstructured":"Chu, C.; Dokou, E.; Haseltine, E. L.; Moskowitz, S.; Overhoff, K. A.; Robertson, S.; Waltz, D.\n                      Compositions and methods for treatment of cystic fibrosis\n                      . WO2019010092, 2019."},{"key":"ref138\/cit138","first-page":"263","volume":"51","author":"Grootenhuis P.","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref139\/cit139","unstructured":"NACFC Oct 2016. https:\/\/investors.vrtx.com\/static-files\/ba8e4870-705a-4121-aa02-d83442154ffd."},{"key":"ref140\/cit140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.07.023"},{"key":"ref141\/cit141","unstructured":"PubChem, Bamocaftor\n(VX-659), National Library of Medicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/134393443 (accessed\nSep 30, 2024)."},{"key":"ref142\/cit142","unstructured":"Alcacio, T.; Baek, M.; Grootenhuis, P.; Hadida Ruah, S. S.; Hughes, R. M.; Keshavarz-Shokri, A.; McAuley-Aoki, R.; McCartney, J.; Miller, M. T.; Van Goor, F.; Zhang, B.; Andreson, C.; Cleveland, T.; Frieman, B. A.; Khatuya, H.; Joshi, P. V.; Krenitsky, P. J.; Melillo, V.; Pierre, F. J. D.; Termin, A. P.; Uy, J.; Zhou, J.; Abela, A. R.; Busch, B. B.; Paraselli, P.; Siesel, D. A.\n                      Preparation of benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide derivatives and analogs for use as cystic fibrosis transmembrane conductance regulator modulators\n                      . WO2018064632, 2018."},{"key":"ref143\/cit143","unstructured":"Dhamankar, V.; Dinehart, K. R.; Dokou, E.; Ferris, L. A.; Gopinathan, N.; McCarty, K.; Metzler, C.; Zhang, B.\n                      Preparation of crystalline forms and pharmaceutical compositions comprising them as CFTR modulators for the treatment of cystic fibrosis\n                      . WO2019079760, 2019."},{"key":"ref144\/cit144","unstructured":"Abela, A. R.; Alcacio, T.; Anderson, C.; Angell, P. T.; Baek, M.; Clemens, J. J.; Cleveland, T.; Ferris, L. A.; Grootenhuis, P. D. J.; Gross, R. S.; Gulevich, A.; Hadida Ruah, S. S.; Hsia, C. K.J.; Hughes, R. M.; Joshi, P. V.; Kang, P.; Keshavarz-Shokri, A.; Khatuya, H.; Krenitsky, P. J.; McCartney, J.; Miller, M. T.; Paraselli, P.; Pierre, F. J. D.; Shi, Y.; Shrestha, M.; Siesel, D. A.; Stavropoulos, K.; Termin, A. P.; Uy, J.; Van Goor, F. F.; Young, T. J.; Zhou, J.\n                      Preparation of N-heteroaroylsulfonamide derivatives as cystic fibrosis transmembrane conductance regulator modulators for treatment of cystic fibrosis\n                      . WO2018107100, 2018."},{"key":"ref145\/cit145","unstructured":"Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor\nand ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11\nWith Certain Mutations. Vertex, Jun 9, 2021. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-trikaftar."},{"key":"ref146\/cit146","unstructured":"Vertex Announces Positive Results From\nPivotal Trials of Vanzacaftor\/Tezacaftor\/Deutivacaftor,\nNext-In-Class Triple Combination Treatment for Cystic Fibrosis. Vertex, Feb 5, 2024. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-results-pivotal-trials."},{"key":"ref147\/cit147","unstructured":"PubChem, Vanzacaftor, National Library of\nMedicine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Vanzacaftor (accessed Jul 27, 2024)."},{"key":"ref148\/cit148","unstructured":"Clemens, J. J.; Abela, A. R.; Anderson, C. D.; Busch, B. B.; Chen, W. G.; Cleveland, T.; Coon, T. R.; Frieman, B.; Ghirmai, S. G.; Grootenhuis, P.; Gulevich, A. V.; Hadida Ruah, S. S.; Hsia, C. K.J.; Kang, P.; Khatuya, H.; McCartney, J.; Miller, M. T.; Paraselli, P.; Pierre, F.; Swift, S. E.; Termin, A.; Uy, J.; Vogel, C. V.; Zhou, J.\n                      Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators\n                      . US20190248809, 2019."},{"key":"ref149\/cit149","unstructured":"Altshuler, D. M.; Anderson, C. D.; Chen, W. G.; Clemens, J. J.; Cleveland, T.; Coon, T. R.; Frieman, B.; Grootenhuis, P.; Hadida Ruah, S. S.; Hare, B. J.; Kewalramani, R.; McCartney, J.; Miller, M. T.; Paraselli, P.; Pierre, F.; Robertson, S. M.; Sosnay, P. R.; Swift, S. E.; Zhou, J.\n                      Preparation of macrocyclic compound for treating cystic fibrosis\n                      . WO2020102346, 2020."},{"key":"ref150\/cit150","unstructured":"Iyemperumal, S. K.; Peresypkin, A.; Shi, Y.; Shrestha, M.\n                      Crystalline forms of cftr modulators\n                      . WO2022036060, 2022."},{"key":"ref151\/cit151","unstructured":"Anderson, C. D.; Clemens, J. J.; Cleveland, T.; Coon, T. R.; Frieman, B.; Grootenhuis, P.; Hadida Ruah, S. S.; McCartney, J.; Miller, M. T.; Paraselli, P.; Pierre, F.; Swift, S. E.; Zhou, J.\n                      Modulators of cystic fibrosis transmembrane conductance regulator\n                      . WO2021030555, 2021."},{"key":"ref152\/cit152","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00377"},{"key":"ref153\/cit153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128843"},{"key":"ref154\/cit154","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01790"},{"key":"ref155\/cit155","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00514"},{"key":"ref156\/cit156","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.698358"},{"key":"ref157\/cit157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.09.006"},{"key":"ref158\/cit158","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.2c02729"},{"key":"ref159\/cit159","unstructured":"Altenbach, R. J.; Bogdan, A.; Desroy, N.; Gfesser, G. A.; Greszler, S. N.; Kym, P. R.; Liu, B.; Malagu, K. F.; Merayo Merayo, N.; Pizzonero, M. R.; Searle, X. B.; Van der Plas, S. E.; Wang, X.; Yeung, M. C.; Zhao, G.\n                      Preparation of sulfonyldihydrobenzopyrancarboxamide derivatives and analogs for use as cystic fibrosis transmembrane conductance regulator protein modulators\n                      . WO2018154493, 2018."},{"key":"ref160\/cit160","unstructured":"AbbVie to Host First Quarter 2022 Earnings Conference\nCall, 2022https:\/\/investors.abbvie.com\/events\/event-details\/abbvie-host-first-quarter-2022-earnings-conference-call."},{"key":"ref161\/cit161","unstructured":"PubChem, PTI-801 (Posenacaftor). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/129027688#section=Depositor-Supplied-Patent-Identifiers (accessed Sep 30, 2024)."},{"key":"ref162\/cit162","unstructured":"Munoz, B.; Bastos, C. M.; Parks, D.; Kombo, D.\n                      Preparation of quinolines and related compounds, compositions, and methods for modulating CFTR\n                      . WO2017062581A1, 2017."},{"key":"ref163\/cit163","unstructured":"Parks, D.; Munoz, B.; Bastos, C. M.\n                      Compounds, compositions and methods for increasing CFTR activity\n                      . WO2019071078, 2019."},{"key":"ref164\/cit164","unstructured":"Proteostasis Therapeutics Announces Progression of\nPTI-428 and PTI-801\nto Longer Duration Studies in CF Subjects. GlobeNewswire, Jul 31, 2017. https:\/\/www.globenewswire.com\/news-release\/2017\/07\/31\/1065145\/0\/en\/Proteostasis-Therapeutics-Announces-Progression-of-PTI-428-and-PTI-801-to-Longer-Duration-Studies-in-CF-Subjects.html."},{"key":"ref165\/cit165","unstructured":"Proteostasis Announces Positive Data from\nOngoing Phase 1 Study of\nPTI-801 in Cystic Fibrosis Patients on Background Orkambi Therapy. BioSpace, Jun 6, 2018. https:\/\/www.biospace.com\/article\/releases\/proteostasis-announces-positive-data-from-ongoing-phase-1-study-of-pti-801-in-cystic-fibrosis-patients-on-background-orkambi-therapy\/?s=62."},{"key":"ref166\/cit166","unstructured":"Mel\u00e3o, A. Triple Combo of Proteostasis\u2019 CFTR Modulators May Benefit CF Patients, Phase 1 Trial Shows. Cystic Fibrosis News Today, Mar 20, 2019. https:\/\/cysticfibrosisnewstoday.com\/news\/proteostasis-cftr-modulators-combo-shows-potential-phase-1-trial\/."},{"key":"ref167\/cit167","unstructured":"Proteostasis Form 8-K Filing with SEC.  https:\/\/www.sec.gov\/Archives\/edgar\/data\/1445283\/000119312519305785\/d843213dex991.htm"},{"key":"ref168\/cit168","unstructured":"Hurlbut, G.\n                      Methods of treating CFTR-mediated diseases or disorders\n                      . WO2024097227, 2024."},{"key":"ref169\/cit169","unstructured":"Liao, J.; Munson, M.; Gao, Z.; Hurlbut, G.; Baltzer, S.; Vivet, B.; Freed, B.; Nestler, H. P.; Yeoman, H.; Mechin, I.; Smrcina, M.; Ma, N.; Lebreton, S.; Hartung, R.; Wire, W.; Thurairatnam, S.\n                      5-Membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity and their preparation\n                      . WO2021097057, 2021."},{"key":"ref170\/cit170","doi-asserted-by":"publisher","DOI":"10.1002\/pro.479"},{"key":"ref171\/cit171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2014.07.026"},{"key":"ref172\/cit172","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb882"},{"key":"ref173\/cit173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.10.086"},{"key":"ref174\/cit174","unstructured":"Liao, J.; Munson, M.; Thurairatnam, S.; Hirth, B.; Gao, Z.; Hurlbut, G.; Borcherding, D.; Barrague, M.; Gillespy, T. A.; Gross, A.; Nieduzak, T.; Good, A.; Vaz, R.; Liu, J.; Li, Y.; Metz, M.; Ruvinsky, A.; Kothe, M.\n                      Indole derivatives as CFTR modulator and uses thereof in the treatment of cystic fibrosis and their preparation\n                      . WO2023034946, 2023."},{"key":"ref175\/cit175","unstructured":"Liao, J.; Munson, M.; Thurairatnam, S.; Hirth, B.; Gao, Z.; Hurlbut, G.; Borcherding, D.; Barrague, M.; Gillespy, T. A.; Gross, A.; Good, A.; Vaz, R.; Liu, J.; Li, Y.; Metz, M.; Ruvinsky, A.; Barberis, C.\n                      Indole derivatives as CFTR correctors and their preparation\n                      . WO2023034992, 2023."},{"key":"ref176\/cit176","unstructured":"Sionna\nPipeline, https:\/\/www.sionnatx.com\/pipeline\/(accessed Jul 28, 2024)."},{"key":"ref177\/cit177","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01897"},{"key":"ref178\/cit178","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607137"},{"key":"ref179\/cit179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.02.006"},{"key":"ref180\/cit180","unstructured":"Proteostasis Form 8-K Filing with SEC. http:\/\/pdf.secdatabase.com\/1592\/0001193125-17-005224.pdf, 2017."},{"key":"ref181\/cit181","first-page":"S204","volume":"55","author":"Downey D. G.","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref182\/cit182","unstructured":"Yumanity Therapeutics Completes Reverse Merger with\nProteostasis\nTherapeutics. GlobeNewswire, Dec 20, 2020. https:\/\/www.globenewswire.com\/en\/news-release\/2020\/12\/23\/2150072\/0\/en\/Yumanity-Therapeutics-Completes-Reverse-Merger-with-Proteostasis-Therapeutics.html."},{"key":"ref183\/cit183","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmch.2018.01.001"},{"key":"ref184\/cit184","unstructured":"Altenbach, R. J.; Bogdan, A.; Desroy, N.; Gfesser, G. A.; Greszler, S. N.; Kym, P. R.; Liu, B.; Malagu, K. F.; Merayo Merayo, N.; Pizzonero, M. R.; Searle, X. B.; Van der Plas, S. E.; Wang, X.; Yeung, M. C.; Zhao, G.\n                      Preparation of sulfonyltetrahydronaphthalenecarboxamide derivatives and analogs for use as cystic fibrosis transmembrane conductance regulator protein modulators\n                      . WO2018154519, 2018."},{"key":"ref185\/cit185","unstructured":"Altenbach, R. J.; Bogdan, A.; Couty, S.; Desroy, N.; Gfesser, G. A.; Housseman, C. G.; Kym, P. R.; Liu, B.; Mai, T. T. T.; Malagu, K. F.; Merayo Merayo, N.; Picolet, O. L.; Pizzonero, M. R.; Searle, X. B.; Van der Plas, S. E.; Wang, X.; Yeung, M. C.\n                      Preparation of substituted N-sulfonylcyclopropanecarboxamides as modulators of the cystic fibrosis transmembrane conductance regulator protein\n                      . US20190077784, 2019."},{"key":"ref186\/cit186","unstructured":"Bogdan, A.; Hardee, D. J.; Hodges, T. R.; Korman, H.; Li, H.Q.; Schrimpf, M. R.\n                      Quinoline-cyclopropane amide as modulators of the cystic fibrosis transmembrane conductance regulator proteins and their preparation, pharmaceutical compositions and use in the treatment of cystic fibrosis\n                      . US20220213041, 2022."},{"key":"ref187\/cit187","unstructured":"Hardee, D. J.; Hodges, T. R.; Schmidt, R. G.; Schrimpf, M. R.; Searle, X. B.\n                      Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use\n                      . US20220211692, 2022."},{"key":"ref188\/cit188","unstructured":"Azimioara, M.; Chen, B.; Epple, R.; Hardy, D.; Honda, A.; Lam, P.; Malik, H. A.; Meier, F.; Nguyen, T. N.; Okram, B.; Patel, S.; Rodriguez, R.; Shaw, D.; Shen, Y.; Wu, B.\n                      N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a CFTR-mediated disease\n                      . WO2020128768, 2020."},{"key":"ref189\/cit189","unstructured":"Azimioara, M.; Chen, B.; Epple, R.; Lajiness, J. P.; Mathison, C. J. N.; Nabakka, J.; Nikulin, V. I.; Patel, S.; Phillips, D. P.; Rucker, P. V.; Valiere, A.; Wu, B.; Yan, S.; Zhu, X.\n                      Preparation of N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease\n                      . WO2020161623, 2020."},{"key":"ref190\/cit190","unstructured":"Grant, S. S.; Hederer, B.; Langenickel, T.; Rowlands, D. J.; Strieter, R. M.; Tian, X.\n                      Synthesis of pyridine and pyrazine derivatives for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and bronchiectasis\n                      . US20200383960, 2020."},{"key":"ref191\/cit191","unstructured":"McCartney, J.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Cleveland, T.; Dwight, T. A.; Frieman, B. A.; Grootenhuis, P.; Hadida Ruah, S. S.; Ishihara, Y.; Miller, M. T.; Silina, A.; Zhou, J.\n                      Heteroaromatic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076628, 2022."},{"key":"ref192\/cit192","unstructured":"McCartney, J.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Cleveland, T.; Dwight, T. A.; Frieman, B. A.; Grootenhuis, P.; Hadida Ruah, S. S.; Ishihara, Y.; Miller, M. T.; Silina, A.; Zhou, J.\n                      Sulfonamides as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076629, 2022."},{"key":"ref193\/cit193","unstructured":"Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Dwight, T. A.; Frieman, B. A.; Hadida Ruah, S. S.; Ishihara, Y.; Krenitsky, P.; McCartney, J.; Melillo, V.; Miller, M. T.; Silina, A.; Uy, J.; Zhou, J.; Grootenhuis, P.\n                      Cystic fibrosis transmembrane conductance regulator modulating agents\n                      . WO2020206080, 2020."},{"key":"ref194\/cit194","unstructured":"McCartney, J.; Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Dwight, T. A.; Frieman, B. A.; Grootenhuis, P.; Hadida Ruah, S. S.; Ishihara, Y.; Krenitsky, P.; Miller, M. T.; Pierre, F.; Silina, A.; Uy, J.; Zhou, J.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076621, 2022."},{"key":"ref195\/cit195","unstructured":"McCartney, J.; Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Coon, T. R.; Dwight, T. A.; Fanning, L. T. D.; Frieman, B. A.; Gulevich, A. V.; Hadida Ruah, S. S.; Ishihara, Y.; Khatuya, H.; Krenitsky, P.; Melillo, V.; Miller, M. T.; Paraselli, P.; Pierre, F.; Silina, A.; Tran, J. A.; Uy, J.; Valdez, L.; Vickers, T.; Zhou, J.; Grootenhuis, P.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator\n                      . WO2022076622, 2022."},{"key":"ref196\/cit196","unstructured":"McCartney, J.; Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Dwight, T. A.; Frieman, B. A.; Grootenhuis, P.; Hadida Ruah, S. S.; Ishihara, Y.; Krenitsky, P.; Miller, M. T.; Pierre, F.; Silina, A.; Zhou, J.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076618, 2022."},{"key":"ref197\/cit197","unstructured":"McCartney, J.; Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Coon, T. R.; Dwight, T. A.; Fanning, L. T. D.; Frieman, B. A.; Grootenhuis, P.; Gulevich, A. V.; Hadida Ruah, S. S.; Ishihara, Y.; Khatuya, H.; Krenitsky, P.; Melillo, V.; Miller, M. T.; Paraselli, P.; Pierre, F.; Silina, A.; Tran, J. A.; Uy, J.; Valdez, L.; Zhou, J.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076624, 2022."},{"key":"ref198\/cit198","unstructured":"McCartney, J.; Abela, A. R.; Abraham, S.; Anderson, C. D.; Arumugam, V.; Chau, J.; Clemens, J.; Cleveland, T.; Coon, T. R.; Dinh, A.; Dwight, T. A.; Fanning, L. T. D.; Frieman, B. A.; Hadida Ruah, S. S.; Ishihara, Y.; Krenitsky, P.; Miller, M. T.; Pierre, F.; Silina, A.; Tran, J. A.; Valdez, L.; Zhou, J.; Grootenhuis, P.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022076625, 2022."},{"key":"ref199\/cit199","unstructured":"Clemens, J. J.; Bookser, B. C.; Cleveland, T.; Coon, T. R.; Gallant, M.; Hadida Ruah, S. S.; Laterreur, J.; Melillo, V.; Miller, M. T.; Paraselli, P.; Ramtohul, Y. K.; Reddy, T. J.; Sturino, C.; Valdez, L.; Zhou, J.; Grootenhuis, P.\n                      Macrocyclic compounds as modulators of cystic fibrosis transmembrane conductance regulator and their preparation\n                      . WO2022032068, 2022."},{"key":"ref200\/cit200","unstructured":"Liao, J.; Macor, J.; Topalov, G.; Munson, M.; Thurairatnam, S.; Hirth, B.; Gao, Z.; Hurlbut, G.; Good, A.; Vaz, R.; Liu, J.; Li, Y.; Ruvinsky, A.; Kothe, M.; Borcherding, D.; Bernardelli, P.; Genevois-Borella, A.; Caussanel, F.; Devillers, I.; Nicolai, E.; Slowinski, F.; Thompson, F.; Schwink, L.; Glombik, H.; Guessregen, S.; Podeschwa, M.; Rackelmann, N.; Ruf, S.\n                      Indole derivatives as CFTR modulators and their preparation\n                      . WO2024054840, 2024."},{"key":"ref201\/cit201","unstructured":"Liao, J.; Macor, J.; Topalov, G.; Munson, M.; Thurairatnam, S.; Hirth, B.; Gao, Z.; Hurlbut, G.; Good, A.; Vaz, R.; Liu, J.; Li, Y.; Ruvinsky, A.; Kothe, M.; Borcherding, D.; Schwink, L.; Glombik, H.; Guessregen, S.; Podeschwa, M.; Rackelmann, N.; Ruf, S.\n                      Preparation of macrocyclic compounds, and compositions and methods of using thereof\n                      . WO2024054845, 2024."},{"key":"ref202\/cit202","unstructured":"Liao, J.; Macor, J.; Topalov, G.; Munson, M.; Thurairatnam, S.; Hirth, B.; Gao, Z.; Hurlbut, G.; Good, A.; Vaz, R.; Liu, J.; Li, Y.; Ruvinsky, A.; Kothe, M.; Borcherding, D.; Bernadelli, P.; Genevois-Borella, A.; Caussanel, F.; Devillers, I.; Nicolai, E.; Slowinski, F.; Thompson, F.; Schwink, L.; Glombik, H.; Guessregen, S.; Podeschwa, M.; Rackelmann, N.; Ruf, S.\n                      Preparation of macrocyclic compounds, and compositions and methods of using thereof\n                      . WO2024054851, 2024."},{"key":"ref203\/cit203","unstructured":"FDA Approves\nKALYDECO (ivacaftor), the First Medicine to Treat the Underlying Cause\nof Cystic Fibrosis. Vertex, Jan 31, 2012. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-kalydecotm-ivacaftor-first-medicine-treat."},{"key":"ref204\/cit204","unstructured":"Kalydeco FDA\nLabel, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203188s038lbl.pdf."},{"key":"ref205\/cit205","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.140"},{"key":"ref206\/cit206","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"ref207\/cit207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"ref208\/cit208","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.04.046"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.4c02547","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.4c02547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:35:34Z","timestamp":1739421334000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.jmedchem.4c02547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":208,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,13]]}},"alternative-id":["10.1021\/acs.jmedchem.4c02547"],"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02547","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}